drugset / Trial / NCT02098421

Foley Labor Induction Trial at Term and in PROM

NCT02098421

Phase 1 Completed 312 enrolled Icahn School of Medicine at Mount Sinai
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is considering current standard oxytocin dosing regimen in combination with Foley bulb for cervical ripening is associated with improved outcomes including greater percentage of women delivered within or less than 24 hours. The investigators will also assess other maternal and neonatal outcomes including risk of infection (i.e. chorioamnionitis), bleeding, uterine atony, cesarean delivery and use of regional analgesia. Participants will be randomly assigned to one of the 2 arms of the study: use of oxytocin or no oxytocin while the Foley bulb is in place. As part of standard of care for inductions, Foley bulbs will be placed for all participants. Study participants who are randomly assigned to the use of oxytocin will receive oxytocin at the time the Foley bulb is placed. Study participants randomly assigned to no oxytocin will receive the oxytocin once the Foley bulb is removed. After delivery, information will be collected from participant's chart on the outcome of pregnancy such as gestational age at delivery, type of delivery (vaginal or cesarean section), and baby's outcome (such as birth weight, APGAR scores, and any complications).

Timeline

Start
2014-11
Primary completion
2016-04-18
Completion
2016-04-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide

Indications

No indication recorded.